Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + docetaxel + gemcitabine
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Bevacizumab + docetaxel + gemcitabine is a combination therapy that targets both cell proliferation and vascularization within tumors. This regimen combines the anti-angiogenic effects of bevacizumab (a monoclonal antibody that inhibits vascular endothelial growth factor) with the cytotoxic effects of the chemotherapy agents docetaxel and gemcitabine. The combination is used in the treatment of various cancers including soft tissue sarcoma, non-small cell lung cancer (NSCLC), and has been studied in other malignancies.
- Brand names
- Axtell regimen
- Other names
- Bev + Gem + Doc
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on bevacizumab + docetaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + docetaxel + gemcitabine.